These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 20728763)

  • 1. Cost-effectiveness of stockpiling 23-valent pneumococcal polysaccharide vaccine to prevent secondary pneumococcal infections among a high-risk population in the United States during an influenza pandemic.
    Dhankhar P; Grabenstein JD; O'Brien MA; Dasbach EJ
    Clin Ther; 2010 Aug; 32(8):1501-16. PubMed ID: 20728763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.
    Cho BH; Stoecker C; Link-Gelles R; Moore MR
    Vaccine; 2013 Dec; 31(50):6011-21. PubMed ID: 24148572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands.
    Rozenbaum MH; Hak E; van der Werf TS; Postma MJ
    Clin Ther; 2010 Aug; 32(8):1517-32. PubMed ID: 20728764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23).
    ;
    MMWR Morb Mortal Wkly Rep; 2010 Sep; 59(34):1102-6. PubMed ID: 20814406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New vaccines against otitis media: projected benefits and cost-effectiveness.
    O'Brien MA; Prosser LA; Paradise JL; Ray GT; Kulldorff M; Kurs-Lasky M; Hinrichsen VL; Mehta J; Colborn DK; Lieu TA
    Pediatrics; 2009 Jun; 123(6):1452-63. PubMed ID: 19482754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
    Melegaro A; Edmunds WJ
    Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines].
    Muciño-Ortega E; Mould-Quevedo JF; Farkouh R; Strutton D
    Value Health; 2011; 14(5 Suppl 1):S65-70. PubMed ID: 21839902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumococcal pneumonia and influenza: a deadly combination.
    Klugman KP; Chien YW; Madhi SA
    Vaccine; 2009 Aug; 27 Suppl 3():C9-C14. PubMed ID: 19683658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of influenza and pneumococcal vaccination for Hong Kong elderly in long-term care facilities.
    You JH; Wong WC; Ip M; Lee NL; Ho SC
    J Epidemiol Community Health; 2009 Nov; 63(11):906-11. PubMed ID: 19608558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) during an annual influenza epidemic and influenza pandemic in China.
    Caldwell R; Roberts CS; An Z; Chen CI; Wang B
    BMC Infect Dis; 2015 Jul; 15():284. PubMed ID: 26206275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects.
    Ray GT; Whitney CG; Fireman BH; Ciuryla V; Black SB
    Pediatr Infect Dis J; 2006 Jun; 25(6):494-501. PubMed ID: 16732146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting.
    Mangtani P; Roberts JA; Hall AJ; Cutts FT
    Int J Epidemiol; 2005 Jun; 34(3):565-74. PubMed ID: 15764694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Vaccination of the elderly against pneumococcal disease is cost-efficient. Mass vaccination of all aged 65 and over is recommended].
    Ortqvist A; Jönsson B; Baltussen R; Ament A
    Lakartidningen; 2000 Nov; 97(45):5120-5. PubMed ID: 11116891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher pneumococcal disease vaccination rates needed to protect more at-risk US adults.
    Rehm SJ; Farley MM; File TM; Hall WJ; Hopkins R; Levine OS; Nichol KL; Nuorti P; Zimmerman RK; Schaffner W
    Postgrad Med; 2009 Nov; 121(6):101-5. PubMed ID: 19940420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmaco-economic aspects of vaccination against invasive pneumococcal infections in persons over 65 years of age; review of the literature on cost effectiveness analysis].
    Postma MJ; Heijnen ML; Beutels P; Jager JC
    Ned Tijdschr Geneeskd; 2002 May; 146(18):855-9. PubMed ID: 12038224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine.
    Silfverdal SA; Berg S; Hemlin C; Jokinen I
    Vaccine; 2009 Mar; 27(10):1601-8. PubMed ID: 19146905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of a 3-dose pneumococcal conjugate vaccine program in the province of Quebec, Canada.
    Poirier B; De Wals P; Petit G; Erickson LJ; Pépin J
    Vaccine; 2009 Nov; 27(50):7105-9. PubMed ID: 19786137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The number needed to vaccinate (NNV) and population extensions of the NNV: comparison of influenza and pneumococcal vaccine programmes for people aged 65 years and over.
    Kelly H; Attia J; Andrews R; Heller RF
    Vaccine; 2004 Jun; 22(17-18):2192-8. PubMed ID: 15149776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.
    Lloyd A; Patel N; Scott DA; Runge C; Claes C; Rose M
    Eur J Health Econ; 2008 Feb; 9(1):7-15. PubMed ID: 17333089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.